Search
Called NEXT, the factor plays an important role in handing over RNA to the exosome for destruction.
Learn about MSK’s visionary new cancer engineering PhD Program.
MSK researchers are learning more about how cancer cells can survive undetected for years only to return in new places. These insights will guide future therapies.
After 21 years of dedicated service, Elizabeth McCormick, MSN, RN, CENP, Senior Vice President, Chief Nursing Officer and Enid A. Haupt Chair, Department of Nursing, will retire from MSK at the end of 2021. During her tenure, Ms. McCormick transformed and ultimately redefined the role of nursing at MSK.
Researchers at Memorial Sloan Kettering are developing a new strategy for PET imaging of tumors that could result in new tools to detect and monitor prostate cancer.
The effects of adoptive T cell therapy on mesothelioma and metastatic lung and breast cancers are the focus of a new Memorial Sloan Kettering Cancer Center trial, which, compared to some existing trials of therapy, offers some important differences for patients.
Maria Jasin, a member of the Sloan Kettering Institute’s Developmental Biology Program, discusses her research.
This year, the GSK student-run Experimental Therapeutics Symposium highlighted MSK’s expertise in successfully moving novel therapies from bench to bedside.
A new lung cancer research center has been created at Memorial Sloan Kettering Cancer Center (MSK). The Fiona and Stanley Druckenmiller Center for Lung Cancer Research (DCLCR) is a multidisciplinary research initiative dedicated to developing innovative and more-effective treatments for people with lung cancer.
A protein detected in the urine of children with Wilms’ tumor led to the development of a test to improve diagnosis and treatment.